Donor Risk Index for African American Liver Transplant Recipients With Hepatitis C Virus

被引:12
|
作者
Shores, Nathan J. [1 ]
Dodge, Jennifer L. [2 ]
Feng, Sandy [2 ]
Terrault, Norah A. [2 ]
机构
[1] Tulane Univ, New Orleans, LA 70118 USA
[2] Univ Calif San Francisco, San Francisco, CA 94143 USA
关键词
FIBROSIS PROGRESSION; RACIAL-DIFFERENCES; UNITED-STATES; SURVIVAL; OUTCOMES; GRAFT; INFECTION; IMPACT; IL28B; HCV;
D O I
10.1002/hep.26478
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
African American (AA) liver transplant (LT) recipients with hepatitis C virus (HCV) have higher rates of graft loss than other racial/ethnic groups. The Donor Risk Index (DRI) predicts graft loss but is neither race- nor disease-specific and may not be optimal for assessing donor risk for AA HCV-positive LT recipients. We developed a DRI for AA with HCV with the goal of enhancing graft loss predictions. All U.S. HCV-positive adult AA first deceased donor LTs surviving 30 days from March 2002 to December 2009 were included. A total of 1,766 AA LT recipients were followed for median 2.8 (interquartile range [IQR] 1.3-4.9) years. Independent predictors of graft loss were donor age (40-49 years: hazard ratio [HR] 1.54; 50-59 years: HR 1.80; 60+ years: HR 2.34, P<0.001), non-AA donor (HR 1.66, P<0.001), and cold ischemia time (CIT) (HR 1.03 per hour >8 hours, P=0.03). Importantly, the negative effect of increasing donor age on graft and patient survival among AAs was attenuated by receipt of an AA donor. A new donor risk model for AA (AADRI-C) consisting of donor age, race, and CIT yielded 1-year, 3-year, and 5-year predicted graft survival rates of 91%, 77%, and 68% for AADRI <1.60; 86%, 67%, and 55% for AADRI 1.60-2.44; and 78%, 53%, and 39% for AADRI >2.44. In the validation dataset, AADRI-C correctly reclassified 27% of patients (net reclassification improvement P=0.04) compared to the original DRI. Conclusion: AADRI-C identifies grafts at higher risk of failure and this information is useful for risk-benefit discussions with recipients. Use of AA donors allows consideration of older donors. (Hepatology 2013;58:1263-1269)
引用
收藏
页码:1263 / 1269
页数:7
相关论文
共 50 条
  • [41] Timing of Hepatitis C Antiviral Therapy in Liver Transplant Recipients With Direct-acting Agents
    Suraweera, Duminda
    Saab, Elena G.
    Tong, Myron J.
    Saab, Sammy
    EXPERIMENTAL AND CLINICAL TRANSPLANTATION, 2016, 14 (03) : 243 - 251
  • [42] Treatment of hepatitis C recurrence is less successful in female than in male liver transplant recipients
    Giannelli, Valerio
    Giusto, Michela
    Farcomeni, Alessio
    Ponziani, Francesca R.
    Pompili, Maurizio
    Vigano, Raffaella
    Iemmolo, Rosa Maria
    Donato, Maria F.
    Rendina, Maria
    Toniutto, Pierluigi
    Pasulo, Luisa
    Morelli, Maria Cristina
    De Martin, Eleonora
    Miglioresi, Lucia
    Di Paolo, Daniele
    Fagiuoli, Stefano
    Merli, Manuela
    TRANSPLANT INTERNATIONAL, 2012, 25 (04) : 448 - 454
  • [43] Acquisition time: A key point of hepatitis C virus-related liver disease in renal transplant recipients
    Turan, Ilker
    TURKISH JOURNAL OF GASTROENTEROLOGY, 2012, 23 (06) : 821 - 823
  • [44] Trends and three-year outcomes of hepatitis C virus- viremic donor heart transplant for hepatitis C virus-seronegative recipients
    Ruck, Jessica M.
    Zhou, Alice L.
    Zeiser, Laura B.
    Alejo, Diane
    Durand, Christine M.
    Massie, Allan B.
    Segev, Dorry L.
    Bush, Errol L.
    Kilic, Ahmet
    JTCVS OPEN, 2022, 12 : 269 - 279
  • [45] Trends in use and three-year outcomes of hepatitis C virus-viremic donor lung transplants for hepatitis C virus- seronegative recipients
    Ruck, Jessica M.
    Zeiser, Laura B.
    Zhou, Alice L.
    Chidi, Alexis P.
    Winchester, Sophia L.
    Durand, Christine M.
    Ha, Jinny S.
    Shah, Pali D.
    Massie, Allan B.
    Segev, Dorry L.
    Merlo, Christian A.
    Bush, Errol L.
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2023, 165 (04) : 1587 - 1595.e2
  • [46] Donor history of malignancy: A limited risk for heart transplant recipients
    Rudasill, Sarah E.
    Iyengar, Amit
    Sanaiha, Yas
    Khoury, Habib
    Mardock, Alexandra L.
    Sareh, Sohail
    Benharash, Peyman
    CLINICAL TRANSPLANTATION, 2020, 34 (02)
  • [47] Impact of the donor body mass index on the survival of pediatric liver transplant recipients and Post-transplant obesity
    Perito, Emily Rothbaum
    Rhee, Sue
    Glidden, Dave
    Roberts, John Paul
    Rosenthal, Philip
    LIVER TRANSPLANTATION, 2012, 18 (08) : 930 - 939
  • [48] Interferon-free regimens for the treatment of hepatitis C virus in liver transplant candidates or recipients
    Cholongitas, Evangelos
    Pipili, Chrysoula
    Papatheodoridis, George
    WORLD JOURNAL OF GASTROENTEROLOGY, 2015, 21 (32) : 9526 - 9533
  • [49] Practical Management of Boceprevir and Immunosuppressive Therapy in Liver Transplant Recipients with Hepatitis C Virus Recurrence
    Coilly, Audrey
    Furlan, Valerie
    Roche, Bruno
    Barau, Caroline
    Noel, Coralie
    Bonhomme-Faivre, Laurence
    Antonini, Teresa Maria
    Roque-Afonso, Anne-Marie
    Samuel, Didier
    Taburet, Anne-Marie
    Duclos-Vallee, Jean-Charles
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2012, 56 (11) : 5728 - 5734
  • [50] Effect of kidney donor hepatitis C virus serostatus on renal transplant recipient and allograft outcomes
    Cohen, Jordana B.
    Eddinger, Kevin C.
    Shelton, Brittany
    Locke, Jayme E.
    Forde, Kimberly A.
    Sawinski, Deirdre
    CLINICAL KIDNEY JOURNAL, 2017, 10 (04) : 564 - 572